Canada / Health CanadaMaster research guideAs of: 2026-05-23

What should a foreign manufacturer prepare before applying for a Health Canada medical device licence?

A foreign medical device manufacturer planning Health Canada market entry should prepare six blocks of public-source evidence before engaging a Canadian regulatory consultant or filing a Medical Device Licence (MDL) application. As of 2026-05-23, those blocks are: (1) a written product description and intended-purpose statement; (2) candidate Class I / II / III / IV clues drawn from MDALL and Schedule 1 of SOR/98-282; (3) MDL vs MDEL applicability research based on device class and the firm's role in the supply chain; (4) a candidate similar-licensed-device shortlist from MDALL; (5) a public safety-history scan covering Health Canada Recalls, Advisories, and Medical Device Incident Reports for similar devices; and (6) a forms / fees / MDSAP / recognized-standards reference card so the consultant brief — and the founder budget — start from current Canadian data. Final device class, MDL/MDEL eligibility, licence outcome, and submission strategy decisions belong to your RA/QA team or qualified Canadian consultant in consultation with Health Canada. This guide prepares the inputs, not the determinations.

For founders, manufacturers, RA/QA teams, and regulatory consultants. For RA/QA or consultant review.

This is not regulatory, legal, or compliance advice. TrueMedDevice does not determine device class, MDL/MDEL eligibility, licence outcome, compliance, safety, or effectiveness. We prepare a source-backed evidence pack from public Health Canada, MDALL, and other public sources so qualified RA/QA professionals or regulatory consultants can review and decide.

1. Device description and intended purpose

Health Canada reads the device description and intended-purpose statement at the start of any licence application. The description should cover device type, principle of operation, energy used, materials, components, accessories, and any accompanying software. The intended-purpose statement should name the intended population, intended user, intended environment of use, and intended clinical purpose. These statements anchor every downstream classification, similar-device, and standards decision.

What this surfaces: a Health Canada-style product profile that grounds all subsequent licence pathway research and that a qualified Canadian consultant can review on first reading.

2. Health Canada device class — candidate clues for Class I, II, III, or IV

Schedule 1 of the Medical Devices Regulations (SOR/98-282) classifies medical devices into Class I, II, III, or IV through risk-based rules covering invasiveness, duration of contact, energy used, intended use, and other factors. Candidate device-class clues are surfaced by reading the rule set against the intended purpose and the candidate similar-licensed device set in MDALL.

Multiple candidate classes can plausibly apply, especially for multi-modal devices or devices that combine drug, biologic, or software elements. The right discipline is to capture every plausible candidate as a candidate review point and hand the set to RA/QA or a qualified Canadian consultant for refinement — ultimately the final class is determined when Health Canada accepts a licence application.

What this surfaces: candidate Class I / II / III / IV clues, the SOR/98-282 Schedule 1 rules that point to each candidate, and the MDALL precedents for similar devices already licensed.

3. MDL vs MDEL — which licence applies?

Two distinct licences govern Canadian market entry. An MDL (Medical Device Licence) is required for manufacturers of Class II, III, and IV devices. An MDEL (Medical Device Establishment Licence) is required for importers, distributors, and manufacturers of Class I devices that sell into Canada directly. The same firm may need an MDL for its devices and an MDEL for its establishment activities — these are not mutually exclusive.

The applicability question turns on the candidate device class and on the firm's role in the supply chain. Public Health Canada guidance, the MDEL Bulletin, and the MDL Application guidance documents define the boundaries. The licence pathway research output is a documented candidate applicability with the relevant guidance citations — not a determination.

What this surfaces: MDL/MDEL applicability research notes with citations to public Health Canada guidance, ready for RA/QA or qualified Canadian consultant review.

4. Similar-licensed-device landscape from MDALL

MDALL (the Medical Devices Active Licence Listing) is Health Canada's public registry of medical devices currently or formerly licensed under SOR/98-282. Searching MDALL by device name, manufacturer, licence number, or class surfaces direct similar products and indirect similar products with licence numbers, applicants, classes, and current licence status.

A structured similar-product comparison table built from MDALL entries, plus public manufacturer product pages and IFUs, is the artifact that survives into the Canadian consultant conversation. It is not a determination that a specific licensed device is suitable as a comparator — it is the source-cited input that makes the licence pathway research conversation easier to build.

What this surfaces: a candidate similar-licensed-device shortlist with licence numbers, classes, and source-cited notes for RA/QA or qualified Canadian consultant review.

5. Public safety-history scan — Health Canada recalls, advisories, and incident reports

Health Canada publishes a Recalls and Safety Alerts database, Public Advisories, Foreign Risk Notifications, and a Medical Device Incident Reporting summary. Reading these as a category — not just for a single candidate similar device but for the broader product family — surfaces failure modes, common labelling issues, and recurring inspection findings relevant to Canadian licence pathway research.

Two cautions. First: voluntary incident reports are not incidence rates; reports are unverified and may be biased by reporter attention. Second: absence statements must be scoped and dated. "No open Health Canada Public Advisories found for manufacturer X in covered sources as of 2026-05-23" is the right shape.

What this surfaces: candidate review points for design, risk management, verification & validation, usability, labelling, cybersecurity, and PMS planning — each tied back to a public Health Canada record.

6. Fees, MDSAP / ISO 13485, recognized standards, and consultant brief preparation

Health Canada publishes annual fee schedules for MDL and MDEL applications, with small-business fee reductions in some cases. MDSAP (Medical Device Single Audit Program) certificates covering ISO 13485:2016 are required for manufacturers of Class II, III, and IV devices. Health Canada also publishes guidance documents, recognized standards lists, and category-specific guidance that shape what evidence the licence application must include.

A reference card that pulls together current-year fees, MDSAP requirements, ISO 13485 conformance evidence expectations, candidate recognized standards, and Health Canada's published processing-time targets is the simplest way to keep this surface visible across the licence-application planning phase. Reference-card numbers are dated; confirm against canada.ca before budgeting or scheduling.

What this surfaces: a dated reference card so the consultant brief — and the founder budget — start from current Canadian data.

What TrueMedDevice prepares

The Canada / Health Canada Market-Entry Product Evidence Pack delivers the research above as a source-cited artifact. Each item below is shipped as part of the pack:

✓Health Canada-style product profile (intended purpose, intended population, intended user, intended environment, principle of operation)
✓Candidate device-class clues (Class I / II / III / IV) drawn from public MDALL filings and Schedule 1 of SOR/98-282
✓Candidate MDL vs MDEL applicability research drawn from the firm's role and the device class
✓Similar-licensed-device shortlist from MDALL with licence numbers, manufacturer, status, and class
✓Public safety-history scan (Health Canada Recalls, Advisories, Safety Alerts, Medical Device Incident Reports) — scoped and dated
✓Fees / processing-time / MDSAP / ISO 13485 / recognized-standards reference card (dated)
✓Preparation gap checklist for design, risk, verification, usability, labelling, sterility, biocompatibility, software, cybersecurity, clinical, and PMS evidence categories
✓Source ledger — every claim cited to a public Health Canada or MDALL record with access date
✓Consultant briefing sheet — structured for handoff to qualified RA/QA or qualified Canadian regulatory consultant

What must still be reviewed by qualified RA/QA or qualified Canadian consultants

The pack is research preparation, not regulatory determination. Every item below remains a judgment call made by your RA/QA team or a qualified Canadian consultant in consultation with Health Canada:

→Final device class under SOR/98-282 (Class I, II, III, or IV)
→MDL applicability and the MDL application strategy
→MDEL applicability for the firm's role in the Canadian supply chain
→Whether to engage a Canadian regulatory representative for the application process
→MDSAP audit scope and Auditing Organization selection
→Quality-management-system scope and ISO 13485 conformance evidence
→Risk-management plan (ISO 14971) scope and acceptance criteria
→Labelling, IFU, and marketing-material review for Canadian-market claims
→Inspection-readiness posture and post-market field-action policy
→Final licence outcome — which is Health Canada's determination on the submitted application

This is not regulatory, legal, or compliance advice. TrueMedDevice does not determine device class, MDL/MDEL eligibility, licence outcome, compliance, safety, or effectiveness. We prepare a source-backed Health Canada / MDALL / public-source evidence pack so qualified RA/QA professionals or regulatory consultants can review and decide.

Related Canada research

Frequently asked questions

What is MDALL?

MDALL (the Medical Devices Active Licence Listing) is Health Canada's public registry of medical devices currently or formerly licensed under the Medical Devices Regulations (SOR/98-282). MDALL is searchable by device name, manufacturer, licence number, and class. This guide shows how to compile a candidate similar-licensed-device shortlist from MDALL for RA/QA or consultant review. MDALL records are not a determination that any specific device is suitable as a comparator for your product.

What's the difference between an MDL and an MDEL?

An MDL (Medical Device Licence) is required for manufacturers of Class II, III, and IV medical devices marketed in Canada. An MDEL (Medical Device Establishment Licence) is required for importers and distributors, and for manufacturers of Class I devices that sell directly into Canada. Which licence applies depends on device class and your firm's role in the supply chain. This guide surfaces the applicability context from public Health Canada sources; the licence determination itself remains with your RA/QA team or qualified Canadian consultant in consultation with Health Canada.

Is MDSAP required for a Health Canada Medical Device Licence?

Health Canada requires manufacturers of Class II, III, and IV devices to hold a certificate from the Medical Device Single Audit Program (MDSAP) covering ISO 13485:2016 quality management. The MDSAP certificate is part of the MDL application package. MDSAP audit scope, eligibility, and certification outcomes are determined by MDSAP-recognized Auditing Organizations and Health Canada — this guide surfaces the documentation context from public sources for RA/QA or consultant review.

How do device classes work under SOR/98-282?

Health Canada classifies medical devices into Class I, II, III, or IV based on the risk-based rules in Schedule 1 of SOR/98-282. Class I is the lowest risk; Class IV is the highest. The classification depends on intended use, invasiveness, duration of contact, energy used, and other rule-based factors. This guide surfaces candidate device-class clues from public MDALL filings and applicable classification rules. The final classification is determined when Health Canada accepts a licence application; until then, classification clues are candidate review points for RA/QA or qualified consultants.

What evidence should I bring to a Canadian regulatory consultant?

Before paid Canadian consultant hours, gather: (1) a written intended-purpose statement, (2) candidate Class I/II/III/IV clues with sources, (3) MDL vs MDEL applicability research, (4) a similar-licensed-device shortlist from MDALL with licence numbers and status, (5) a safety-history scan from Health Canada Recalls, Advisories, and Medical Device Incident Reports, and (6) a fees / processing-time / MDSAP / recognized-standards reference. The Product Evidence Pack delivers each of these as a source-cited artifact. Class, MDL/MDEL eligibility, licence outcome, and submission strategy decisions remain with your RA/QA team or qualified Canadian consultant.

Want this research run on your product for Health Canada?

The Canada / Health Canada Market-Entry Product Evidence Pack delivers the workflow above — product profile, candidate device-class clues, MDL/MDEL applicability research, similar-licensed-device shortlist from MDALL, safety-history scan, forms/fees/MDSAP/standards reference, source ledger, and consultant briefing sheet — as a source-cited artifact for qualified RA/QA or qualified Canadian consultant review.

See the Canada / Health Canada Market-Entry Product Evidence Pack